HbA1c, insulin use predict real-world response to GLP-1 receptor agonists in type 2 diabetes

A patient’s response to GLP-1 receptor agonist therapy in type 2 diabetes depends on several pretreatment characteristics, including baseline HbA1c, diabetes duration, age and use of insulin therapy, according to a real-world analysis published in Current Medical Research and Opinion.

Source: HbA1c, insulin use predict real-world response to GLP-1 receptor agonists in type 2 diabetes

About the Author

Stephanie Figon, MS, RDN, LD

Founder of NutriScape.NET. As a dietitian since 1992, Steph Figon has had experiences in consulting, 15 years in clinical, and has operated a private practice nutrition counseling office for since 2011. The RDNutriScape Instagram

Tags:

Related Posts